Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM

Verona Pharma plc
Posted on: 09 Mar 18

March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended 31 December 2017 ("2017 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been posted to Shareholders.

The Company confirms that a copy of its 2017 Annual Report and Accounts and Notice of Annual General Meeting are available online at www.veronapharma.com. The Notice of Annual General Meeting can also be found within the AIM Rule 26 section of the website.

The Annual General Meeting of Verona Pharma will be held at the London offices of Nasdaq, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA at 9.00 a.m. on 2 May 2018.

-Ends-

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

  Verona Pharma plc
Tel: +44 (0)20 3283 4200
  Jan-Anders Karlsson, Chief Executive Officer
info@veronapharma.com

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 

Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com

  FTI Consulting (UK Media and Investor enquiries)
Tel: +44 (0)20 3727 1000
  Simon Conway / Natalie Garland-Collins
veronapharma@fticonsulting.com

  
  
  
  
  
  
 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire
HUG#2175222
GlobeNewswire
globenewswire.com

Last updated on: 11/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.